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Enhanced Therapeutic Effects 
of Human iPS Cell Derived-
Cardiomyocyte by Combined 
Cell-Sheets with Omental Flap 
Technique in Porcine Ischemic 
Cardiomyopathy Model
Masashi Kawamura1, Shigeru Miyagawa1, Satsuki Fukushima1, Atsuhiro Saito2, Kenji Miki1, 
Shunsuke Funakoshi3, Yoshinori Yoshida3, Shinya Yamanaka3, Tatsuya Shimizu4,  
Teruo Okano4, Takashi Daimon5, Koichi Toda1 & Yoshiki Sawa1
Transplant of human induced pluripotent stem cell derived cardiomyocytes (hiPS-CMs) cell-sheet is a 
promising approach for treating ischemic cardiomyopathy (ICM). However, poor blood supply to the 
transplanted cell-sheet is a concern related to the effectiveness and durability of the treatment. Herein, 
we hypothesized that the combined the omentum flap might enhance survival and the therapeutic 
effects of hiPS-CM cell-sheet transplant for ICM treatment. Treatment by Wnt signaling molecules 
in hiPS cells produced hiPS-CMs, which were magnetically labeled by superparamagnetic iron oxide 
(SPIO), followed by culture in the thermoresponsive dishes to generate hiPS-CMs cell-sheets. A porcine 
ICM model included 4 groups; sham operation, omentum flap only, cell-sheet only, or combination 
therapy. Ejection fraction (EF) was significantly greater in the cell-sheet only and combination group 
compared to the other groups during the follow-up period. At 3 months, the EF of the combination 
group was significantly greater than that of the cell-sheet only group. Consistently, the survival rate 
of the SPIO-labeled hiPS-CMs, as assessed by MRI, was significantly greater in the combination group 
than in the cell-sheet only group. This cell delivery system would be useful in optimizing the hiPS-CM 
cell-sheet transplant for treating severe heart failure.
Stem cell therapy has recently emerged for treating heart failure, and numerous preclinical and clinical studies 
using various types of stem cells have been proven to improve cardiac functions and attenuate left ventricular 
remodeling1–3. However, the ideal cell type or the optimum cell delivery method is still unknown1–3. We have 
demonstrated that advantages of cell-sheet technique as a cell delivery method in stem cell therapy for the treat-
ment of heart failure4. This technique preserves extra cellular matrix without artificial scaffolds, which may 
prevent cell detachment -associated “anoikis”5. In contrast to the myocardial needle injection, the cell-sheet tech-
nique can deliver a large number of cells to failed heart with high retention rate of transplanted cells and minimal 
injury to the host myocardium6, 7.
Human induced pluripotent stem (hiPS) cells, which have a capacity of unlimited proliferation and differen-
tiation to cardiomyocyte8, 9, are promising cell source for myocardial regeneration therapy10. We have explored a 
new strategy of myocardial regeneration therapy using hiPS cells and cell-sheet technique to aim a more effective 
stem cell therapy for heart failure. We demonstrated the feasibility and therapeutic efficacy of transplantation of 
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human iPS-derived cardiomyocytes (hiPS-CMs) sheet for a porcine ischemic cardiomyopathy model11, however, 
long-term engraftment of transplanted cells has remained to be concerned11. This poor engraftment of the trans-
planted cells is considered to be resulted from ischemia caused by poor vascularization of the transplanted sites 
and inflammation with attendant oxidative stress and release of cytotoxic cytokines1–3. To overcome the issue of 
long-term engraftment of transplanted cells, we have focused on the omentum, because the omentum is known 
to be a vascular-rich organ, contain abundant angiogenic factors, and have anti-inflammatory effects12. We have 
expected the omentum as a blood supply source, and reported that combination of the pedicle omentum flap with 
cell-sheet enhanced the survival of transplanted hiPS-CMs in an uninjured porcine heart13.
Herein, we hypothesized that the pedicle omentum flap technique may enhance survival of hiPS-CMs and the 
therapeutic capacity of hiPS-CM sheet transplant in a porcine ischemic cardiomyopathy model. In this study, we 
compared survival of hiPS-CMs after transplantation in a diseased heart, with or without the pedicle omentum 
flap, and we also investigated whether improvement of cardiac functions increased by the additive omentum flap 
compared with the hiPS-CM sheet itself in a porcine cardiomyopathy model.
Results
Cardiomyogenic differentiation of hiPS cells and cell-sheet generation. Differentiation of hiPS 
cells into cardiomyocytes was induced by treatment of the embryoid bodies formed from cultured hiPS cells 
with Wnt3a and R-spondin-1 in thermoresponsive dishes (10-cm Upcell dishes). Subsequently, the differentiated 
hiPS cells were purified by culture in glucose-free medium to yield 1–2 × 107 hiPS-CMs. Approximately 80% 
(84.6 ± 6.8%) of the hiPS-CMs were positive for cardiac troponin T (cTNT), as determined by flow cytometry 
(Fig. 1a), and evidence of sarcomeres among the hiPS-CMs was demonstrated by immunocytochemistry with an 
anti-sarcomeric alpha actinin antibody (Fig. 1b). Human mesenchymal stem cells (hMSCs) are known to have the 
potential to induce immunologic tolerance14 and enhance the structural characteristics of engineered tissue15, 16. 
Therefore, to fill the cell-free space in the Upcell dishes and to aid in lifting up the cell sheets, we added hMSCs to 
the hiPS-CM culture, and incubated the dishes at room temperature, which induced spontaneous detachment of 
the cells into scaffold-free hiPS-CM cell sheets. Immunohistolabeling showed that the large number of cells in the 
hiPS-CM cell sheets were homogeneously positive for cTNT (Fig. 1c).
Functional recovery in a porcine ICM model after the treatment assessed by serial CMR. We 
established a porcine ICM model by placement of an ameroid constrictor (COR-2.50-SS, Research Instruments) 
around the left anterior descending coronary artery in mini-pigs (Japan Farm) through a left thoracotomy17. 
Four weeks after MI induction, we treated them via median sternotomy under general anesthesia. All animals 
were immunosuppressed by daily administration of tacrolimus (0.75 mg/kg, Astellas), mycophenolate mofetil 
(500 mg, Teva Chech Industries s.r.o,), and predonisolone (20 mg, Takeda Pharmaceutical Co Ltd.) daily from 
5 days before the treatments until sacrifice. The experimental workflow was shown in Fig. 2. The treatments 
included 4 options, and 23 mini-pigs with MI were randomly divided into 4 treatment groups: cell-sheets with 
the omentum flap (SO group = 7), cell-sheet only (S group = 6), the omentum flap only (O group = 5), or sham 
Figure 1. Characterization of hiPS-CMs and hiPS-CM cell sheet. (a) Expression of cardiac troponin T (cTNT) 
after differentiation and purification of hiPS-CMs was determined by flow cytometry anaysis. (b) After 
differentiation and purification, sarcomere structure was visualized by sarcomeric alpha actinin staining in 
hiPS-CM. (c) Immunostaining of the hiPS-CM cell sheet with cTNT antibody (green). The cell nuclei were 
counterstained with 4′,6-diamidino-2-phenylindole (DAPI; blue). Scale bar, 10 μm in (b) and 100 μm in (c).
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operation (Sham group = 5). We prepared hiPS-CM sheet, as previously described11, 13, 18. The hiPS-CMs were 
labeled with the superparamagnetic iron oxide (SPIO) ferucarbotran (Resovist; Bayer Pharma), by using the 
hemagglutinating virus of Japan envelope (HVJ-E) vector (GenomeOne-Neo, Ishihara Sangyo)19, 20. We success-
fully performed the treatments, and there was no mortality related to the procedure or otherwise prior to the 
planned sacrifice. To evaluate cardiac functions after the treatments, we performed serial cardiac magnetic res-
onance imaging (CMR) on the same mini-pigs prior to (baseline) and 1 month, 2 month, and 3 months after 
treatments, and evaluated in LVEF, LV end-diastolic volume (LVEDV), and LV end-systolic volume (LVESV). The 
baseline LVEF, LVEDV, and LVESV did not differ significantly between the 4 groups. The sham operation and the 
omentum only group showed no improvement in LVEF during follow-up period (LVEF at baseline, 1 M, 2 M, 3 M; 
Sham group: 36.9 ± 1.2%, 36.0 ± 3.0%, 34.5 ± 4.4%, 33.1 ± 3.7%, O group: 35.9 ± 5.5%, 33.9 ± 4.2%, 34.0 ± 4.2%, 
33.9 ± 2.0%, Fig. 3a). The sheet only group and combination therapy showed improvement in LVEF compared 
with other groups (LVEF at baseline, 1 M, 2 M, 3 M; S group: 35.7 ± 2.6%, 50.1 ± 2.7%, 48.9 ± 3.5%, 44.9 ± 1.6%, 
SO group: 36.8 ± 2.0%, 52.6 ± 4.9%, 52.8 ± 4.7%, 52.1 ± 4.5%, p < 0.0001 for interaction effect of time and group 
in the repeated ANOVA, Fig. 3a). Subsequently, improvement in LVEF remained in the combination therapy 
over 3 months, in contrast, LVEF gradually reduced in the sheet only group in the meantime. LVEF at 3 months 
was significantly greater in the combination therapy than in the sheet only group (52.1 ± 4.5% versus 44.9 ± 1.6%, 
P < 0.01, Fig. 3a). In addition, LVEDV at 3 months in combination group showed significantly smaller than those 
in the sham group (51.3 ± 10.3 ml versus 68.4 ± 12.1 ml, p < 0.05, Fig. 3b). LVESV at 3 month in the sheet only 
and the combination therapy showed significantly smaller than that in the sham group (Fig. 3c), and LVESV at 3 
months were significantly smaller in the combination therapy than in the sheet only group (24.5 ± 5.3 ml versus 
33.0 ± 4.8 ml, P < 0.05, Fig. 3c).
Regional wall motions assessed by serial CMR after the treatments. The porcine ICM model in 
the present study had the infarct lesion, the infarct-border lesion, and the infarct-remote lesion. It is an important 
aspect which lesions the treatment have effects on to investigate underlying mechanisms of the stem cell therapy. 
We evaluated regional wall motions at baseline and 3 months after the treatments, which obtained by serial CMRs, 
Figure 2. Study protocol of the mini-pig experiments. Schedule of cardiac magnetic resonance imaging (CMR) 
and histological evaluations.
Figure 3. CMR analysis for global cardiac functions: LVEF in a, LVEDV in b, and LVESV in c. (a) LVEF at 3 
months was significantly greater in the SO group than in the S group. (b) LVEDV at 3 months in combination 
group showed significantly smaller than those in the sham group. (c) LVESV at 3 month in the S and SO group 
showed significantly smaller than that in the sham group. LVESV at 3 months were significantly smaller in the 
SO group than in the S group. †p < 0.05, *p < 0.01.
www.nature.com/scientificreports/
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using the specialized software. The whole heart was divided to 9 regions including the left anterior descending 
artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) area at each base, mid, and 
apex level, which were determined referring a standardized LV segmentation model. Any regions in the sham and 
the omentum only groups were not improved during the follow-up periods. In the sheet only group, improve-
ments of regional wall motions were demonstrated in 3 regions including Base-LCX (20 ± 5% versus 30 ± 6%, 
p < 0.01), Mid-LCA (26 ± 6% versus 37 ± 7%, p < 0.01) and Mid-RCA area (27 ± 6% versus 41 ± 8%, p < 0.001, 
Baseline versus 3 months, Fig. 4b,e,f). On the other hand, in the combination therapy, improvements of regional 
wall motions were observed in 6 regions including Base-LAD (13 ± 4% versus 25 ± 5%, p < 0.001), Base-LCX 
(24 ± 6% versus 37 ± 8%, p < 0.01), Base-RCA (10 ± 4% versus 23 ± 6%, p < 0.001), Mid-LAD (15 ± 4% ver-
sus 37 ± 8%, p < 0.0001), Mid-LCX (27 ± 7% versus 51 ± 9%, p < 0.0001), and Mid-RCA area (32 ± 7% versus 
55 ± 9%, p < 0.001, Baseline versus 3 months, Fig. 4a–f). Any regional wall motions at apex level had not changed 
significantly in all treatment groups (Fig. 4g–i). These suggest that the combination therapy had broad therapeutic 
effects compared with the sheet only group, but the infarct lesions were not improved.
Figure 4. CMR analysis for regional wall motions (a–i). Regional wall motions at baseline and at 3months after 
treatments were compared. In the S group, improvements of regional wall motions were demonstrated in 3 
regions in (b,e,f). In the SO group, improvements of regional wall motions were observed in 6 regions in (a–f). 
Any regional wall motions at apex level had not changed significantly in all treatment groups in (g–i). †p < 0.05, 
*p < 0.01, ‡p < 0.001, §p < 0.0001 vs. baseline.
www.nature.com/scientificreports/
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In vivo analysis of survival of the transplanted SPIO-labeled hiPS-CMs by serial CMR. We also 
performed serial CMRs to assess the survival of the transplanted SPIO-labeled hiPS-CMs, and tracked intensity of 
SPIO signal from hiPS-CMs at 1 week (baseline), 1 month, 2 months, and 3 months after the cell transplantation.
SPIO-signals were clearly identified as the hypointense area in the surface of the left ventricle by CMR in all 
mini-pigs during the study period (Fig. 5a). SPIO-positive hypointense area was gradually decreased in the both 
groups over the 3 months, while SPIO-positive area was larger and thicker in the combination therapy compared 
with the sheet only group during the study period. The survival proportion of the SPIO-labeled hiPS-CMs was 
determined by the formula that the hypointense area at 1, 2 and 3 months after transplantation was divided by the 
area at 1 week after transplantation as baseline. Both groups showed steady decrease in the cell survival over the 
3 months, whereas proportion in the decrease was significantly less in the combination therapy than in the sheet 
only group at 1 month (89 ± 9% versus 61 ± 11%), 2 months (75 ± 9% versus 42 ± 9%) and 3 months (57 ± 10% 
versus 25 ± 5%) after the treatment (P < 0.0001 for interaction effect of time and group in the repeated ANOVA, 
Fig. 5b). Prussian blue staining demonstrated iron-contained cells on the surface of the heart corresponding to 
Figure 5. In vivo analysis of the survival of SPIO-labeled hiPS-CMs after transplantation. (a) Serial CMRs 
were examined at 1 week (baseline), 1 month, 2 months, and 3 months after SPIO-labeled hiPS-CM cell-sheet 
transplantation, with or without the omentum. (b) Cell survival proportion was estimated by the SPIO-labeled 
area at 1 month, 2 months and 3 months, corrected by cell survival at 1 week. (c,d) Cells containing iron, 
indicative of SPIO-labeled hiPS-CMs, were detected by Prussian Blue staining of sections of the S group (c) or 
the SO group (d) at the transplanted area; bar = 50 μm in (c,d).
www.nature.com/scientificreports/
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the area seen on CMR in both groups. A large number of cells with iron contents were identified in the combina-
tion therapy (Fig. 5c,d).
hiPS-CM sheet with the omentum covering demonstrated increased capillary density, and 
upregulation of VEGF, SDF-1, and bFGF expression in the transplanted area 3 months after 
transplant. The combination of the omentum improved the survival rate of hiPS-CMs as shown in Fig. 5. It 
is expected that the omentum could improve the ischemic environment for the hiPS-CMs after transplant, and 
support hiPS-CMs with nutrition diffusion from its vasculatures and by secreting angiogenetic factors12, 13. We 
visualized vessels and capillaries in the sheet only and the combination therapy at 3 months after the treatment, 
and assessed semi-quantitatively by immunohistochemistry for vWF. In fact, capillary density in the transplanted 
site was significantly and markedly greater in the combination therapy (111 ± 35 units/mm2) than in the sheet 
only group (51 ± 22 units/mm2, P < 0.05, Fig. 6a–c). In addition, we investigated the expression level of cardiopro-
tective and angiogenic factors in the transplanted area at 3 months after the treatment, and quantitatively assessed 
by real-time PCR for VEGF, SDF-1, and bFGF. Relative expression of all the factors in the transplanted site was 
significantly greater in the combination therapy than in the sheet only group (VEGF; 1.41 ± 0.26 vs 1.02 ± 0.22, 
P < 0.05, SDF-1; 1.81 ± 0.53 vs 1.06 ± 0.24, P < 0.05, bFGF; 1.59 ± 0.68 vs 0.99 ± 0.26, P < 0.05, Fig. 7a–c).
The omentum covering supported maturation of transplanted hiPS-CMs in vivo. We used 
enhanced green fluorescent protein (EGFP)-labeled hiPS cells, which contains the sequence of EGFP driven 
by myosin heavy chain 6 (MYH6) promoter21, to create the cell-sheets, and to investigate phenotypic fate of the 
hiPS-CMs after transplant. We performed the cell-sheet transplant for MI induced mini-pigs with the omentum 
covering. Two weeks after transplantation with combination therapy, abundant EGFP and MYH double-positive 
cells were observed in the transplanted area (Fig. 8a–d). These cells were also positive for myosin light chain-2 
(MYL, Fig. 8e–g). However, sarcomere structure was not clearly observed. In specimens obtained 2 months 
after transplant, double-positive cells were also detected, and a well-aligned, well-organized sarcomere structure 
was observed in these cells (Fig. 8h–n), which suggests that the omentum covering supported maturation of 
hiPS-CMs in vivo.
Discussion
It is herein demonstrated that the combination of hiPS-CM cell-sheet and the omentum flap had higher and 
longer therapeutic effects compared with the sole hiPS-CM cell-sheet therapy in a porcine ischemic cardiomyo-
pathy model. The number of surviving hiPS-CMs was significantly greater in the MI-induced mini-pigs with the 
omentum than those without it, although there was a stable reduction in the surviving cell number independent 
of the omentum support, as investigated by SPIO cell-labelling with CMR. The additive omentum covering to 
the hiPS-CM cell-sheet transplantation markedly increase the number of vessels and capillaries, associated with 
upregulation of VEGF, bFGF and SDF-1, at the transplanted site on the damaged heart compared to the hiPS-CM 
cell-sheet transplantation without the omentum. In the analysis using EGFP-labeled hiPS cells, although 
Figure 6. Capillary density in the transplanted area. (a) The capillary density in the transplanted area was 
significantly greater in the SO group than in the S group. Photomicrographs of immunostaining for von 
Willebrand factor are shown in (b,c); bar = 100 μm. A. †p < 0.05, vs. the S group.
www.nature.com/scientificreports/
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implanted cardiomyocytes which were transplanted 2 weeks after implantation has immature features such as 
poor sarcomeres or cytosols, some of the transplanted hiPS-CMs got matured and synthesized well-organized 
sarcomere in vivo in the MI-induced mini-pigs with the omentum flap 3 months after transplant.
Conditions in the host heart would influence the survival of transplanted cells after delivery, which could 
limit the therapeutic effects and outcomes of stem cell therapy1–3. Especially, the hostile ischemic environment 
is assumed, when the cells are delivered in the infarcted myocardium without blood supply. In our previous 
work, combination of cell-sheet technique with the omentum flap enhanced the cell survival after transplan-
tation in a porcine uninjured heart13. In this study, the combination method also enhanced the survival of the 
delivered cells even in the damaged myocardium, and angiogenesis and expression of angiogenesis related factors 
were increased in the transplanted area. In addition, cell-sheet transplantation with the omentum flap better 
promoted arteriogenesis and stabilized blood vessels in ischemic myocardium along with improved coronary 
microcirculation physiology22. It was also reported that the omentum had not only angiogenic cytokines but also 
anti-inflammatory properties and thus facilitated tissue healing of injured tissue or organs23. These results sug-
gest that transplanted cells might be provided sufficient blood supply, nutrients diffusion and anti-inflammatory 
effects from the omentum tissue regardless of conditions of the host myocardium. Several strategies are currently 
under investigation to improve cell survival, and engraftment. They include that genetic modification of the cells24 
or implantation of the cells in scaffolds made of biocompatible matrix25. The pedicled omentum flap is frequently 
used in clinical settings, such as a treatment of mediastinitis after cardiovascular surgery. Therefore, our combi-
nation method might take an advantage of easily translating to clinical application on a standpoint of regulatory 
science.
Human embryonic stem (ES) cell or hiPS cell-derived cardiomyocytes structurally and electronically inte-
grated to the host myocardium after cell transplant via needle injections in large animal studies26–29. We also 
demonstrated that iPS-CM cell-sheets integrated to the host myocardium after transplant30, and this is one of the 
most important factors in the mechanisms of stem cell derived cardiomyocyte therapy for heart failure. These 
transplanted cells are necessary to survive long-term with enough graft size to contribute to the host myocardium 
contraction. In the current study, the cell-sheet combined with the omentum flap could transfer large number 
of hiPS-CMs on the heart, and higher and longer therapeutic effects were demonstrated compared with sole 
cell-sheet transplant. Especially, with the omentum flap, loss of the transplanted cells in early phase was pre-
vented, however, the survival rate of the transplanted cells were gradually decreased in late phase. It would be 
considered that chronic rejection caused the decrease in the cell survival in late phase. In recent non-human 
primate studies, allogenic iPS-CMs with homozygous MHC haplotype transplanted in non-human primates with 
heterozygous MHC haplotype by MHC-matched fashion26, 28. MHC-matched allogenic iPS-CM transplant with 
immunosuppressant drugs demonstrated high cell retaining rate 2 months after the cell transplant31 or no evi-
dence of rejection during 3 month-observation period29. Given manufacturing and regulatory restriction, and 
clinical application for acute disease, allogenic cell transplant is a realistic method. Though long-term survival of 
a large number of the transplanted allogenic cells is still challenging, enough blood supply in early phase such as 
the omentum flap and optimal immune suppression including MHC-matched cell transplant and immunosup-
pressant drug regimen are mandatory.
Transdifferentiation of mesenchymal stem cells or cardiac stem cells into cardiomoyocytes in the heart after 
transplantation are controversial32–34. Therefore, cardiomyocytes differentiated from ES cells or iPS cells in 
vitro are promising cell sources to replenish cardiomyocyte into the failing heart. The relationship between the 
iPS-CMs differentiation level and the engraftment capacity was investigated in the iPS-CM transplant study using 
severe immunodeficiency mice (NOG mice)21, and the iPS-CMs purified at day 20 from initiation of differen-
tiation had a higher engraftment rate than those purified at day 8 or day 3021. In addition, the day20 iPS-CMs 
were proliferated in early phase and maturated in vivo from 3 to 6 months after the transplant21. It was confirmed 
that there was the optimal differentiated stage (not too immature and not too-closely mature) in iPS-CMs for 
enhancing engraftment rate and maximizing therapeutic efficacy21, that is, in vivo maturation of iPS-CMs would 
be necessary in cell therapy using iPS-CMs. In the current study, transplanted hiPS-CMs became larger and 
Figure 7. Angiogenesis-related mRNA expression in the transplanted area, as measured by RT-PCR. (a–c) 
Relative expression of angiogenesis-related factors at the transplanted area was significantly greater in the SO 
group than in the S group (a). VEGF, †P < 0.05; (b) SDF-1, †P < 0.05; (c) bFGF, †p < 0.05 vs. the S group).
www.nature.com/scientificreports/
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synthesized sarcomere 2 months after transplant with the omentum compared with 2 weeks after transplant. It 
suggests that some of the transplanted cells got matured in vivo, even though xenogeneic transplant model. It 
might be because the omentum provides good environment to some of the transplanted cells possibly via blood 
supply and induction of immunologic tolerance. Given this standpoint, the omentum flap is a useful cell-delivery 
method in cardiac regeneration therapy.
In conclusions, the pedicle omental flap covering enhanced survival of hiPS-CMs in vivo and produced longer 
therapeutic effects at post-transplantation in a porcine ischemic cardiomyopathy model. This cell delivery system 
would be useful in optimizing hiPS-CM cell-sheet transplantation therapies for treating severe heart failure.
Materials and Methods
Animal care procedures were consistent with the Guide for the Care and Use of Laboratory Animals (NIH). 
Experimental protocols were approved by Ethics Review Committee for Animal Experimentation of Osaka 
University Graduate School of Medicine (reference no. 23-002-0).
Culture and cardiomyogenic differentiation of human iPS cells, magnetic labeling, and 
cell-sheet preparation. The human iPS (hiPS) cell line 201B7 that was generated using the 4 transcription 
factors Oct4, Sox2, Klf4, and c-Myc was used in this study8. Culture of the hiPS cells, formation of the embryoid 
bodies (EBs), and subsequent cardiomyogenic differentiation11, 13 and purification18 were carried out to generate 
hiPS cell-derived cardiomyocytes (hiPS-CM), as previously described in our works11, 13. The purified hiPS-CMs 
were then labeled with the superparamagnetic iron oxide (SPIO) ferucarbotran (Resovist; Bayer Pharma, Berlin, 
Figure 8. The EGFP labeled hiPS-CMs after transplantation with the omentum. (a–g) Detection of EGFP-
labeled hiPS-CMs 2 weeks after transplantation; representative photomicrographs showing HE stain (a), GFP in 
green (b,e), myosin heavy chain (MYH) and myosin light chain-2 (MYL) in red (c,f). (h–n) Detection of EGFP-
labeled hiPS-CMs 2 months after transplantation; representative photomicrographs showing HE stain (h), GFP 
in green (i,l), and MYH and MYL in red (j,m). The nuclei were stained with DAPI in blue (b–g,i–n). Merged 
images are shown in (d,g,k,n). Bar = 100 μm in (a,h), 10 μm in (b–g,i–n).
www.nature.com/scientificreports/
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Germany), by using the hemagglutinating virus of Japan envelope (HVJ-E) vector (GenomeOne-Neo, Ishihara 
Sangyo, Osaka, Japan)19, 20. Subsequently, human mesenchymal stem cell (hMSC; Lonza, Basel, Switzerland) 
were seeded at a density of 5 × 106 cells/dish onto 10-cm UpCell dishes (CellSeed, Tokyo, Japan), on which 
the SPIO-labeled hiPS-CMs were grown. The next day, the dishes were incubated at room temperature, which 
induced the cells to detach spontaneously to form scaffold-free hiPS-CM cell-sheets.
An enhanced green fluorescent protein (EGFP) labeled hiPS cell line was also used for phenotypic fate truck-
ing in this study. This iPS cells contains the sequence of EGFP driven by myosin heavy chain 6 (MYH6) pro-
moter21. EGFP labeled hiPS-CM cell-sheets were created with same protocols described as above.
Flow cytometry analysis and immunocytochemistry of hiPS-CMs. Cells dissociated after hiPS cell 
differentiation were fixed, permeabilized, and labeled with the an antibody against cardiac troponin T (cTNT; 
clone 13211; Thermo Fisher Scientific, Runcorn, UK) conjugated with Alexa-488 using Zenon technology 
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), followed by analysis on a BD FACSCanto II (BD 
Biosciences, Franklin Lakes, NJ) with BD FACSDiva Software (BD Biosciences).
To characterize the differentiated cells from the hiPS cells, immunocytochemical analysis of sarcomeric 
alpha actinin (ACT; 1:100 dilution, Abcam) was performed. Antibody-labelled cells were visualized with an 
AlexaFluor555-conjugated goat anti-mouse secondary antibody, and cells were counterstained with DAPI, and 
imaged with a confocal microscope (FluoView FV10i, Olympus Japan).
Generation of a porcine ischemic cardiomyopathy model and Study protocol. A chronic myo-
cardial infarction (MI) model was generated by placement of an ameroid constrictor (COR-2.50-SS, Research 
Instruments) around the left anterior descending coronary artery in female mini-pigs (Japan Farm) weighing 
20 to 25 kg17. Four weeks after MI induction, treatments were performed via median sternotomy under gen-
eral anesthesia. All animals were immunosuppressed by daily administration of tacrolimus (0.75 mg/kg, Astellas, 
Tokyo, Japan), mycophenolate mofetil (500 mg, Teva Chech Industries s.r.o, Opava, Chech), and predonisolone 
(20 mg, Takeda Pharmaceutical Co Ltd., Osaka, Japan) daily from 5 days before transplantation until sacrifice. 
Twenty-eight mini-pigs were induced for MI, and mini-pigs of LVEF with 30–40% were included in this study. 
Total 5 mini-pigs were excluded due to early death for 3, LVEF with more than 40% for 1, and LVEF with less 
than 30% for 1 mini-pig. The remaining 23 mini-pigs with MI were randomly divided into 4 treatment groups: 
cell-sheets with the omentum flap (SO group = 7), cell-sheet only (S group = 6), the omentum flap only (O 
group = 5), or sham operation (Sham group = 5). The overall work flow of the study was shown in Fig. 2.
Procedural protocols of transplant of SPIO-labeled hiPS-CM cell-sheets covered with or with-
out the omentum flap. The procedures were described in the previous manuscript13. Briefly, all animals 
were pre-anesthetized with ketamine hydrochloride (20 mg/kg, DAIICHI SANKYO, Tokyo, Japan) and xylazine 
(2 mg/kg, Bayer HealthCare, Leverkusen, Germany), intubated endotracheally, and maintained by a continu-
ous infusion of propofol (6 mg/kg/h; AstraZeneca K.K., Osaka, Japan) and vecuronium bromide (0.05 mg/kg/h; 
DAIICHI SANKYO). Seven SPIO-labeled hiPS-CM sheets were placed on the epicardium via the median sternot-
omy. In the cases of transplantation of the cell-sheet covered with the omentum flap, the omentum was mobilized 
to the mediastinal space via additional small upper midline laparotomy, preserving both gastroepiploic arteries 
and their arcade. Initially, all of 7 hiPS-CM cell-sheets were placed on the epicardium, and covered with the 
omentum. The omentum was stitched and fixed on the excised pericardium. The mini-pigs were then allowed to 
recover and were later humanely sacrificed.
We induced MI on 4 mini-pigs in addition to previous 28 mini-pigs, and transplant EGFP-labeled hiPS-CM 
cell-sheets with the omentum flap to investigate phenotypic fate of the transplanted hiPS-CMs. Those animals 
were humanely sacrificed at 2 weeks or 4 weeks after transplant for histological study (2 animals each).
Cardiac magnetic resonance imaging. Electrocardiogram-gated cardiac magnetic resonance imag-
ing (CMR) was performed under general anesthesia with an 8-channel cardiac coil wrapped around the chest 
wall32. CMR images were acquired on a 1.5T MR scanner (Signa EXCITE XI TwinSpeed; GE Medical Systems, 
Milwaukee, Wisconsin). All image analyses were performed using a specialized workstation (Virtual Place 
Lexus64; AZE, Tokyo, Japan). We evaluated LVEF, LVEDV, and LVESV before (as baseline), and 1 month, 
2months, and 3 months after treatment. To investigate left ventricular regional wall motion, each short-axis slice 
was divided into 6 segments at base and mid level or 4 segments at apex level, referring a standardized left ven-
tricular segmentation model from American Heart Association guideline35, 36.
To assess SPIO-labeled hiPS-CM detection, animals were imaged 1 week after transplantation. In addition, 1 
animal was re-imaged at 1 month, 2 months, and 3 months after transplantation to detect SPIO-labeled hiPS-CM 
retention. Short-axis images with 8-mm slice thickness, including the entire heart, were obtained by pulse param-
eters for cardiac-gated, fast gradient-recalled echo (FGRE). The SPIO-labeled hiPS-CM hypointense area was 
measured using planimetry of FGRE images on the workstation (Virtual Place Lexus64). The survival proportion 
of hiPS-CMs was determined using the hypointense area at 1 month, 2 months, and 3 months after transplant 
divided by the area at 1 week after transplant as the baseline.
Histology and immunohistochemistry. The hiPS-CM cell-sheets and the excised heart specimens 
were either embedded in paraffin, or in OCT compound (TissuebTek; Sakura Finetek, Torrance, CA) for frozen 
section. The paraffin-embedded sections were stained with hematoxylin-eosin (HE) or prussian blue that vis-
ualizes iron contents. In addition, the paraffin-embedded sections were immunolabeled with anti-human von 
Willebrand factor (vWF) antibody (FLEX Polyclonal Rabbit Anti-Human Von Willebrand Factor, Ready-to-Use; 
Dako Omnis, Glostrup, Denmark) and visualized with the horseradish peroxidase-based EnVision kit (Dako). 
Ten different fields were randomly selected, and the number of vWF-positive cells in each field was counted using 
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a light microscope under high-power magnification (×200). The stained blood vessels from the 10 fields were 
averaged and the results expressed as vascular density (per square millimeter). The frozen sections were immu-
nolabeled with monoclonal anti-Myosin antibody (MYH; 1:100 dilution, SIGMA, St.Louis MO), anti-Myosin 
Light Chain2 antibody (MYL, 1:200 dilution, Abcam, Cambridge, UK), and anti-GFP antibody (1:100 dilution, 
Abcam) as primary antibodies, and visualized with AlexaFluor488-conjugated goat anti-mouse (Invitrogen) and 
AlexaFluor555-conjugated goat anti-rabbit (Invitrogen) as secondary antibodies. Nuclei were counterstained 
with by 4′,6-diamidino-2-phenylindole (DAPI, Dojindo, Tokyo, Japan), and assessed using a fluorescence micro-
scope (Biorevo BZ-9000, Keyence, Osaka, Japan) or a confocal microscope (Olympus Japan, FluoView FV10i, 
Tokyo, Japan).
Real-time polymerase chain reaction. Total RNA was extracted from cardiac tissue and reverse tran-
scribed using Omniscript reverse transcriptase (Qiagen, Hilden, Germany) with random primers (Invitrogen), 
and the resulting cDNA was used for real-time polymerase chain reaction (RT-PCR) with the ABI PRISM 
7700 (Applied Biosystems, Stockholm, Sweden) system using pig-specific primers (Applied Biosystems) 
for vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and stromal derived 
factor-1 (SDF-1). Each sample was analyzed in triplicate for each gene studied. Data were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression level. For relative expression analysis, the 
ddCT method was used, and values of the cell-sheet transplantation without the omentum were used as reference 
values.
Statistical analysis. Data are expressed as means ± standard deviations (SDs). Comparisons between 2 
groups were made using Welch’s t test and within-group differences were compared with the paired t test. LVEF 
in global cardiac function and cell survival proportion over time was assessed by repeated-measures analysis of 
variance (ANOVA) with group, time, and group×time interaction effects. The paired t test was used for post-hoc 
test in repeated-measures ANOVA. All probability values are 2-sided and values of P < 0.05 were considered to 
indicate statistical significance. Statistical analyses were performed using JMP 12.2 (SAS Institute, Cary, NC).
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